Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node RadiationMonika L. Metzger, Matthew J. Krasin, Torunn I. Yock et al.|Journal of Clinical Oncology|2021Cited by 59
Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08Jamie E. Flerlage, M Link, Angela M. Feraco et al.|Blood|2026Cited by 2
Excellent Outcome for Pediatric Patients with High Risk Hodgkin Lymphoma with Brentuximab Vedotin and Risk Adapted Residual Node RadiationMonika L. Metzger, Matthew J. Krasin, Michael P. Link et al.|SSRN Electronic Journal|2020Cited by 0
METABOLIC-ONLY RESPONSE ASSESSMENT ALLOWS FOR OMISSION OF RESIDUAL NODE RADIATION THERAPY (RNRT) FOR THE MAJORITY OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) WHILE MAINTAINING EXCELLENT EVENT FREE (EFS) AND OVERALL SURVIVAL (OS): A REPORT FROM THE PEDIATRIC HODGKIN CONSORTIUM’S PHASE 2 STUDY cHOD17 (NCT03755804)Jamie E. Flerlage, Matthew J. Ehrhardt, Angela M. Feraco et al.|Leukemia Research|2025Cited by 0